Comparison Overview
ARIAD Pharmaceuticals, Inc.

ARIAD Pharmaceuticals, Inc.
26 Landsdowne Street, Cambridge, 02139, US
Last Update: 01/04/2026
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is now part of Takeda Pharmaceuticals.

Bristol Myers Squibb
3401 Princeton Pike, Lawrence Township, 08648, US
Last Update: 20/05/2026
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds i...
Compliance Ranges Comparison

ARIAD Pharmaceuticals, Inc.







Bristol Myers Squibb






Benchmark & Cyber Underwriting Signals
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for ARIAD Pharmaceuticals, Inc. in 2026.
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for Bristol Myers Squibb in 2026.
Incident History - ARIAD Pharmaceuticals, Inc. (X = Date, Y = Severity)
ARIAD Pharmaceuticals, Inc. cyber incidents detection timeline including parent company and subsidiaries.
Incident History - Bristol Myers Squibb (X = Date, Y = Severity)
Bristol Myers Squibb cyber incidents detection timeline including parent company and subsidiaries.
Notable Incidents

ARIAD Pharmaceuticals, Inc.

Bristol Myers Squibb
FAQ
Latest Global CVEs
PraisonAI before 1.5.115 contains a path traversal vulnerability in MultiAgentMonitor that fails to sanitize agent IDs when building file paths. Attackers can include traversal sequences like ../ in agent IDs to read, write, or overwrite arbitrary files, enabling sensitive disclosure, denial of service, or code execution.
PraisonAI before 1.5.115 contains an information disclosure vulnerability in the MultiAgentLedger component that allows attackers to access sensitive data by registering agents with duplicate IDs. Attackers can exploit the lack of agent ID uniqueness enforcement to share ledger instances and expose system prompts and conversation history between agents.
PraisonAI before 1.5.128 contains a cross-origin agent execution vulnerability in the AGUI endpoint that allows remote attackers to trigger arbitrary agent execution. The POST /agui endpoint lacks authentication and hardcodes Access-Control-Allow-Origin: * headers, combined with Starlette's Content-Type-agnostic JSON parsing, enabling attackers to bypass CORS preflight checks via simple requests and exfiltrate sensitive agent responses including tool execution results and environment data.
PraisonAI before 4.5.128 contains an arbitrary shell command execution vulnerability where the UI modules hardcode approval_mode to auto, overriding administrator configuration from PRAISON_APPROVAL_MODE environment variable. Authenticated attackers can instruct the LLM agent to execute arbitrary shell commands via subprocess.run with shell=True, bypassing the manual approval gate and insufficient command sanitization blocklists.
PraisonAI before 1.5.128 caches tool approval decisions by tool name only, not by invocation arguments, allowing subsequent execute_command calls to bypass approval prompts. Attackers can exploit this by obtaining initial approval for a benign command, then silently exfiltrate API keys and credentials via subsequent shell commands without user consent.